ATRIVA Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop new antiviral therapies against different severe respiratory viral infections, an area of high unmet medical need.
ATRIVA’s lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, potentially also coronaviruses. ATR-002 is under clinical development in influenza and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects.
The Company owns nine broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2039.
ATRIVA Therapeutics is located in Tübingen and Frankfurt, Germany.